Axolabs GmbH

Company

    • Company type:
      • Research & Development
    • Year founded:
    • 2000
    • Employees (at the site):
    • 59
    • Turnover range:
    • 5m - <10m EUR
    • Products/services:
    • Technology
      Besides other RNA-based approaches, Roche Kulmbach GmbH is currently focused on therapeutics based on the principle of RNA Interference (RNAi). RNAi is a recently discovered natural and catalytic mechanism for selectively silencing genes encoding proteins that play harmful roles in disease. RNAi is triggered by siRNAs, which are short double-stranded RNA molecules. A sequence-specific target mRNA-recognition by the siRNA leads to the cleavage and subsequent degradation of the mRNA and thus prevents the production of the encoded protein.
      siRNAs have the potential to become a whole new class of innovative therapeutics. In principle, by using RNAi it is possible to silence any given gene in the genome, including as yet "undruggable" target genes.

      Products
      Roche Kulmbach GmbH is currently focused on the discovery of novel RNA therapeutics for the treatment of oncological, respiratory and metabolic diseases.

    • Core competencies:
    • Roche Kulmbach GmbH is Roche's Center of Excellence for the discovery and development of new therapeutics on the basis of ribonucleic acids (RNA). Currently, Roche Kulmbach GmbH focuses on a new class of therapeutics based on the principle of RNA interference (RNAi). RNAi is a natural process to selectively silence endogenous genes and is mediated by small interfering RNAs (siRNAs). Roche Kulmbach GmbH uses synthetic siRNAs to specifically silence disease-associated genes. This universal approach is applied to develop novel therapeutics for the treatment of oncological, respiratory and metabolic diseases.

      Roche Kulmbach GmbH was the first company worldwide to focus on the therapeutic potential of RNA interference. Scientists at Roche Kulmbach AG have excellent know-how about the discovery and development of RNAi therapeutics, propelled by the experience gained from 2003-2007 when they were part of the Alnylam Pharmaceuticals organization, a world-leading company in RNAi.

    • Language skills:
    • English
      German
    • Key Tech / section:
      • Biotechnology: Technical services for biotechnology
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72.11: Research and experimental development on biotechnology
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Roland Kreutzer (Mr.)
      - Management

      Dipl. Kfm. Andreas Bossko (Mr.)
      - Management